State Health Investment Project: Impact Evaluation Endline Survey, 2017
Nigeria, 2017
Get Microdata
Reference ID
NGA_2017_HRBFIE-EL_v01_M
Producer(s)
Eeshani Kandpal (World Bank)
Created on
Dec 05, 2022
Last modified
Aug 28, 2024
Page views
101024
Downloads
313
- Data files
- cardio_drugs_noid.dta
- Catchment_Area_noid.dta
- decr_services_noid.dta
- diagnostic_kits_noid.dta
- FP_drugs_noid.dta
- general_drugs_noid.dta
-
Health Facility
(HF1)_noid.dta - HF1_Sect08_noid.dta
- HF1_sect10A_noid.dta
- HF1_Sect10B_noid.dta
- incr_services_noid.dta
- interview_actions_noid.dta
- interview_comments_noid.dta
- malaria_drugs_noid.dta
- obstetric_care_noid.dta
- Q1611_positions_noid.dta
- services_noid.dta
- TB_drugs_noid.dta
- vaccines_noid.dta
- anc_patients_noid.dta
- HF3_HCP_Info_noid.dta
- HF4_HCP_Info_noid.dta
- HF4_patients_noid.dta
- interview_actions_noid.dta
- interview_comments_noid.dta
-
Patient DIRECT
OBSERVATION
(HF3_HF4)_noid.dta - HF5_ASSETS_noid.dta
- HF5_LIVESTOCK_noid.dta
- HF5_patients_noid.dta
- HF6_ASSETS_noid.dta
- HF6_LIVESTOCK_noid.dta
- HF6_patients_noid.dta
- interview_actions_noid.dta
- interview_comments_noid.dta
-
Patient EXIT
INTERVIEW
(HF5_HF6)_noid.dta -
Health Care
Provider
Interviews
(HF7)_noid.dta - HF7_Q202_noid.dta
- interview_actions_noid.dta
- interview_comments_noid.dta
- staff_roster_noid.dta
- Durable_Goods_noid.dta
- hhroster_noid.dta
- interview_actions_noid.dta
- interview_comments_noid.dta
-
NSHIP IE
Midline
Household Women
Questionnaire_noid.dta - Q16_13_noid.dta
- S5C_Assets_noid.dta
- S9_Vaccines_noid.dta
- Sec_05B_noid.dta
- Sec_06A_noid.dta
- Sec_06B_noid.dta
- Sec_06C_noid.dta
- Sec_07_noid.dta
Originator (Originator)
Data file: interview_comments_noid.dta
Overview
Valid:
2423
Invalid:
-
Type:
Discrete
Start:
3
End:
14
Width:
12
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| AD1_HF1 | 13 |
0.5%
|
|
| AD10_HF1 | 13 |
0.5%
|
|
| AD11_HF1 | 5 |
0.2%
|
|
| AD11_HF1_NEW | 31 |
1.3%
|
|
| AD12_HF1 | 17 |
0.7%
|
|
| AD13_HF1 | 29 |
1.2%
|
|
| AD14_HF1 | 26 |
1.1%
|
|
| AD15_HF1 | 4 |
0.2%
|
|
| AD2_HF1 | 33 |
1.4%
|
|
| AD3_HF1 | 19 |
0.8%
|
|
| AD4_HF1 | 83 |
3.4%
|
|
| AD5_HF1 | 6 |
0.2%
|
|
| AD6_HF1 | 29 |
1.2%
|
|
| AD7_HF1 | 6 |
0.2%
|
|
| AD8_HF1 | 5 |
0.2%
|
|
| AD9_HF1 | 23 |
0.9%
|
|
| BN1_HF1 | 16 |
0.7%
|
|
| BN2_HF1 | 10 |
0.4%
|
|
| BN3_HF1 | 5 |
0.2%
|
|
| NS1_HF1 | 6 |
0.2%
|
|
| NS3_HF1 | 31 |
1.3%
|
|
| NS4_HF1 | 6 |
0.2%
|
|
| NS5_HF1 | 12 |
0.5%
|
|
| NS6_HF1 | 60 |
2.5%
|
|
| OG1_HF1 | 310 |
12.8%
|
|
| OG2_HF1 | 117 |
4.8%
|
|
| OG3_HF1 | 11 |
0.5%
|
|
| OG4_HF1 | 349 |
14.4%
|
|
| ON1_HF1 | 44 |
1.8%
|
|
| ON2_HF1 | 261 |
10.8%
|
|
| ON3_HF1 | 5 |
0.2%
|
|
| ON4_HF1 | 38 |
1.6%
|
|
| ON5_HF1 | 218 |
9%
|
|
| ON6_HF1 | 79 |
3.3%
|
|
| ON7_HF1 | 284 |
11.7%
|
|
| ON8_HF1 | 89 |
3.7%
|
|
| TR1_HF1 | 46 |
1.9%
|
|
| TR2_HF1 | 18 |
0.7%
|
|
| TR3_HF1 | 31 |
1.3%
|
|
| TR4_HF1 | 35 |
1.4%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.